News headlines about Acorda Therapeutics (NASDAQ:ACOR) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Acorda Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.2002138865372 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media stories that may have impacted Accern’s analysis:

Shares of Acorda Therapeutics (NASDAQ:ACOR) traded up 3.70% on Thursday, reaching $26.65. The company’s stock had a trading volume of 663,661 shares. The company’s market cap is $1.24 billion. Acorda Therapeutics has a 12-month low of $13.60 and a 12-month high of $33.00. The company’s 50 day moving average price is $23.03 and its 200 day moving average price is $19.84.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.16. Acorda Therapeutics had a negative return on equity of 6.37% and a negative net margin of 8.02%. The firm had revenue of $139.40 million for the quarter, compared to analysts’ expectations of $139.81 million. During the same period in the previous year, the firm posted $0.07 EPS. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. Analysts forecast that Acorda Therapeutics will post $1.71 EPS for the current fiscal year.

Several equities research analysts recently commented on ACOR shares. Cowen and Company restated an “outperform” rating and set a $35.00 target price on shares of Acorda Therapeutics in a research report on Wednesday, June 7th. BidaskClub upgraded Acorda Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, July 7th. Jefferies Group LLC began coverage on Acorda Therapeutics in a report on Monday, July 10th. They issued a “hold” rating and a $22.00 price target on the stock. Zacks Investment Research lowered Acorda Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 19th. Finally, Stifel Nicolaus reiterated a “buy” rating on shares of Acorda Therapeutics in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $24.29.

COPYRIGHT VIOLATION NOTICE: This article was first reported by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at

In other news, Director Barry E. Greene sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $21.57, for a total value of $215,700.00. Following the sale, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $215,700. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Scopia Capital Management Lp purchased 766,201 shares of the company’s stock in a transaction dated Tuesday, August 29th. The stock was bought at an average cost of $19.23 per share, for a total transaction of $14,734,045.23. The disclosure for this purchase can be found here. Insiders own 7.90% of the company’s stock.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.